BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 3209865)

  • 1. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
    Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
    Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis.
    Gentiloni N; Caradonna P; Costamagna G; D'Ostilio N; Perri V; Mutignani M; Febbraro S; Tinari N; Iacobelli S; Natoli C
    Am J Gastroenterol; 1995 Jul; 90(7):1069-72. PubMed ID: 7611198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F; Roscher R; Beger HG
    Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.
    Matsubayashi H; Canto M; Sato N; Klein A; Abe T; Yamashita K; Yeo CJ; Kalloo A; Hruban R; Goggins M
    Cancer Res; 2006 Jan; 66(2):1208-17. PubMed ID: 16424060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular diagnosis in pancreatic carcinoma].
    Dítĕ P; Lukás Z; Hermanová M; Kroupová I; Kleibl Z; Brázdil J; Pazourková M; Novotný Z; Růzicka M
    Vnitr Lek; 2003 Jul; 49(7):559-62. PubMed ID: 12931440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
    Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
    Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
    Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma].
    Nouts A; Lévy P; Voitot H; Bernades P
    Gastroenterol Clin Biol; 1998 Feb; 22(2):152-9. PubMed ID: 9762189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J; Arkosy P; Lenkey A; Sápy P
    Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytology in the diagnosis of pancreatic cancer.
    Del Favero G; Fabris C; Angonese C; Basso D; Rebuffi A; Costantin G; Matarazzo R; Di Mario F; Naccarato R
    Int J Pancreatol; 1988; 3 Suppl 1():S137-41. PubMed ID: 3209868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis.
    Malesci A; Tommasini MA; Bonato C; Bocchia P; Bersani M; Zerbi A; Beretta E; Di Carlo V
    Gastroenterology; 1987 Jan; 92(1):60-7. PubMed ID: 3465666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
    Markocka-Maczka K
    Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.